The group acquired PacificGMP, a contract manufacturing business, in September and contract chemist TCRS in December.
Bookings through both have been strong and have benefited from access to Abzena's immunogenicity assessment, antibody engineering and manufacturing technologies.
In January, Abzena's ThioBridge arm, a specialist in linking antibodies to other drugs, signed a licence agreement that could see it earn up to US$150mln in fees, royalties and milestone payments from an unnamed partner.
It has also just teed up a marketing alliance with antibody discovery services company, FairJourney Biologics (Portugal) to offer antibody discovery services and with FairJourney Biologics to offer immunogenicity assessment and analytics.
Abzena also has interests in eleven drugs currently under development, two of which are in phase II trials.
John Burt, chief executive, said: "Progress has been strong during the period.
“The agreement for ThioBridge with a large US biotech company demonstrates the value of our proprietary technology in creating novel ADCs. We continue to find new ways of expanding our range of offerings, by working with specialists such as FairJourney Biologics.
“We expect to maintain this level of momentum for the foreseeable future,” he added.